Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

The mechanistic target of rapamycin (mTOR) is an established therapeutic target in renal cell carcinoma (RCC). Mechanisms of secondary resistance to rapalog therapy in RCC have not been studied previously. We identified six patients with metastatic RCC who initially responded to mTOR inhibitor thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamieh, Lana, Choueiri, Toni K., Ogórek, Barbara, Khabibullin, Damir, Rosebrock, Daniel, Livitz, Dimitri, Fay, Andre, Pignon, Jean-Christophe, McDermott, David F., Agarwal, Neeraj, Gao, Wenhua, Signoretti, Sabina, Kwiatkowski, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181431/
https://www.ncbi.nlm.nih.gov/pubmed/30256787
http://dx.doi.org/10.1371/journal.pgen.1007679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181431/
https://www.ncbi.nlm.nih.gov/pubmed/30256787
http://dx.doi.org/10.1371/journal.pgen.1007679

Ejemplares similares